Affiliation:
1. College of Pharmacy, University of Illinois, Chicago, IL 60012, USA
2. DEI Biopharma, Kampala P.O. Box 35854, Uganda
Abstract
Therapeutic proteins treat many acute and chronic diseases that were until recently considered untreatable. However, their high development cost keeps them out of reach of most patients around the world. One plausible solution to lower-cost manufacturing is to adopt newer technologies like using Escherichia coli to express larger molecules, including full-length antibodies, generally relegated to Chinese Hamster Ovary (CHO) cells, adopt continuous manufacturing, and convert the manufacturing to cell-free synthesis. The advantages of using E. coli include a shorter production cycle, little risk of viral contamination, cell host stability, and a highly reproducible post-translational modification.
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference165 articles.
1. Recombinant Human Insulins–Clinical Efficacy and Safety in Diabetes Therapy;Landgraf;Eur. Endocrinol.,2016
2. (2023, July 10). Approved Protein Drugs in the US and EU. Available online: https://drugs.ncats.io/.
3. Therapeutic proteins;Dimitrov;Methods in Molecular Biology,2012
4. Strategies for efficient production of recombinant proteins in Escherichia coli: Alleviating the host burden and enhancing protein activity;Zhang;Microb. Cell Fact.,2022
5. Zhang, J., Zhao, Y., Cao, Y., Yu, Z., Wang, G., Li, Y., Ye, X., Li, C., Lin, X., and Song, H. (2020). Synthetic sRNA-based engineering of Escherichia coli for enhanced production of full-length immunoglobulin G. Biotechnol. J., 15.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献